Key Drivers
- Strong Profitability
- Improving Liquidity
- Elevated Leverage
AIAI Summary
BMY's strong cash flow, dividend, and newer-brand growth make it a credible portfolio-replacement story rather than a pure patent-cliff decline, but the investment hinges on whether launches can scale fast enough to offset looming Eliquis and Opdivo erosion while reducing leverage. Investors should favor confirmation of sustained new-brand growth and a break above $65.66, while treating pipeline upside as unproven until regulatory, manufacturing, and adoption milestones are met.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Profitability
- •Improving Liquidity
- •Elevated Leverage
BMY offers strong margins, cash flow, liquidity and dividend appeal, but substantial leverage and intangible exposure warrant balance-sheet caution.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Oversold momentum
- •Key support
BMY remains bearish below its last-month average, but oversold RSI and $62.80–$63.10 support could spur a rebound; watch $64.70 resistance and avoid renewed downside if support breaks.
Declined 5.9% over the recent month
Sentiment & News
Key News Insights:
- •Portfolio Transition
- •Guidance Raised
- •Patent Exposure
Bristol Myers Squibb's newer brands, raised guidance, and promising pipeline support growth, but legacy-product erosion and Eliquis patent risk remain key overhangs.
The outlook is cautiously positive, though sustained upside depends on new-product execution offsetting upcoming patent-driven declines
Similar Companies in Healthcare
Other companies in the same sector with AI ratings